ArticleProceedings of the National Academy of Sciences of the United States of America2021
GHB analogs confer neuroprotection through specific interaction with the CaMKIIα hub domain.
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Discovery of a novel CaMKⅡα inhibitor by machine learning, molecular docking and molecular dynamics simulation.Journal of computer-aided molecular design · 2026Article
- S-nitros(yl)ation of CaMKIIα and its precision redox regulation by SNOTAC plays a critical role in learning and memory.Redox biology · 2025Article
- HOCPCA Exerts Neuroprotection on Retinal Ganglion Cells by Binding to CaMKIIα and Modulating Oxidative Stress and Neuroinflammation in Experimental Glaucoma.Neuroscience bulletin · 2025Article
- Radiofluorinated Analogs of NCS-382 as Potential PET Tracers for Imaging the CaMKIIα Hub Domain.ACS chemical neuroscience · 2025Article
- The neuroprotective γ-hydroxybutyrate analog 3-hydroxycyclopent-1-enecarboxylic acid does not directly affect CaMKIIα autophosphorylation at T286 or binding to GluN2B.Molecular pharmacology · 2025Article
- The Glutamate/GABA-Glutamine Cycle: Insights, Updates, and Advances.Journal of neurochemistry · 2025Review
- Ligand-induced CaMKIIα hub Trp403 flip, hub domain stacking, and modulation of kinase activity.Protein science : a publication of the Protein Society · 2024Article
- Hub stability in the calcium calmodulin-dependent protein kinase II.Communications biology · 2024Article
- Studying CaMKII: Tools and standards.Cell reports · 2024Review
- Ca2+/CaM dependent protein kinase II (CaMKII)α and CaMKIIβ hub domains adopt distinct oligomeric states and stabilities.Protein science : a publication of the Protein Society · 2024Article
- Photoactivated Protein Degrader for Optical Control of Synaptic Function.ACS chemical neuroscience · 2023Article
- Article
- Article
- The GHB analogue HOCPCA improves deficits in cognition and sensorimotor function after MCAO via CaMKIIα.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Article
- N-Terminomic Changes in Neurons During Excitotoxicity Reveal Proteolytic Events Associated With Synaptic Dysfunctions and Potential Targets for Neuroprotection.Molecular & cellular proteomics : MCP · 2023Article
- An Overview of the Putative Structural and Functional Properties of the GHBh1 Receptor through a Bioinformatics Approach.Life (Basel, Switzerland) · 2023Article
- Sodium Oxybate for Alcohol Dependence: A Network Meta-Regression Analysis Considering Population Severity at Baseline and Treatment Duration.Alcohol and alcoholism (Oxford, Oxfordshire) · 2023Review
- A Photoactivated Protein Degrader for Optical Control of Synaptic Function.bioRxiv : the preprint server for biology · 2023Article
- CaMKII as a Therapeutic Target in Cardiovascular Disease.Annual review of pharmacology and toxicology · 2023Review
- CaMKIIα as a Promising Drug Target for Ischemic Grey Matter.Brain sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Ulrike LeursDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-8828-3505
Anders B KleinDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-0236-3089
Ethan D McSpaddenHHMI, University of California, Berkeley, CA 94720.ORCID 0000-0002-8705-9341
Nane Griem-KreyDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.
Sara M Ø SolbakDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.ORCID 0000-0003-0233-7160
Josh HoultonDepartment of Anatomy, Brain Health Research Centre and Brain Research New Zealand, University of Otago, 9054 Dunedin, New Zealand.ORCID 0000-0002-6443-572X
Inge S VillumsenDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.
Stine B VogensenDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-9136-4955
Louise HamborgDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-8580-9751
Stine J GaugerDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.
Line B PalmelundDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-5325-9169
Anne Sofie G LarsenDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.
Mohamed A ShehataDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.
Christian D KelstrupProteomics Program, Faculty of Health and Medical Sciences, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, DK-2200 Copenhagen, Denmark.
Jesper V OlsenProteomics Program, Faculty of Health and Medical Sciences, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, DK-2200 Copenhagen, Denmark.
Anders BachDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.ORCID 0000-0003-4305-9910
Robert O BurnieDepartment of Anatomy, Brain Health Research Centre and Brain Research New Zealand, University of Otago, 9054 Dunedin, New Zealand.
D Steven KerrDepartment of Pharmacology and Toxicology, University of Otago, 9054 Dunedin, New Zealand.ORCID 0000-0001-6325-0996
Emma K GowingDepartment of Anatomy, Brain Health Research Centre and Brain Research New Zealand, University of Otago, 9054 Dunedin, New Zealand.
Selina M W TeurlingsDepartment of Neuroscience, Erasmus University Medical Center, 3015 GD, Rotterdam, The Netherlands.
Chris C ChiHHMI, University of California, Berkeley, CA 94720.ORCID 0000-0001-9382-0910
Christine L GeeHHMI, University of California, Berkeley, CA 94720.
Bente FrølundDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.
Birgitte R KornumDepartment of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.ORCID 0000-0002-2515-9451
Geeske M van WoerdenDepartment of Neuroscience, Erasmus University Medical Center, 3015 GD, Rotterdam, The Netherlands.ORCID 0000-0003-2492-9239
Rasmus P ClausenDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark.
John KuriyanHHMI, University of California, Berkeley, CA 94720.
Andrew N ClarksonDepartment of Anatomy, Brain Health Research Centre and Brain Research New Zealand, University of Otago, 9054 Dunedin, New Zealand.ORCID 0000-0003-3804-3834
Petrine WellendorphDepartment of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2100 Copenhagen, Denmark; pw@sund.ku.dk.ORCID 0000-0002-5455-8013
Funding
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6MEliminating Critical Systematic Errors In Structural Biology With Next-Generation SimulationR01GM124149 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOLTON, JAMES M · 2017 to 2024
$2.5MNIGMS NIH HHS P30 GM124169NIGMS NIH HHS R01 GM124149
Abstract
Ca
Indexed as
Binding SitesCalcium-Calmodulin-Dependent Protein Kinase Type 2Carboxylic AcidsCrystallography, X-RayCyclopentanesGene Expression Regulation, EnzymologicHEK293 CellsHumansNeuroprotectionProtein BindingProtein DomainsSignal TransductionSodium Oxybate3-hydroxycyclopent-1-enecarboxylic acidCalcium-Calmodulin-Dependent Protein Kinase Type 2Carboxylic AcidsCyclopentanesSodium OxybateexcitotoxicityHOCPCAphotoaffinity labelingphotothrombotic strokex-ray crystallography
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.